Washington 2025-2026 Regular Session

Washington Senate Bill SB5577

Introduced
1/29/25  
Refer
1/29/25  
Report Pass
2/13/25  
Engrossed
2/28/25  
Refer
3/4/25  
Report Pass
3/19/25  
Refer
3/21/25  
Enrolled
4/1/25  
Chaptered
4/4/25  

Caption

AN ACT Relating to medicaid coverage for HIV antiviral drugs;

Summary

SB 5577 requires Washington’s Medicaid authority to cover all FDA-approved HIV antiviral drugs without prior authorization or step therapy. The coverage mandate applies both to fee-for-service Medicaid clients and to clients enrolled in managed care plans. The bill also requires managed care systems contracting with the authority to provide the same unrestricted coverage for these drugs when contracts are initiated or renewed. The measure is framed as an act concerning Medicaid coverage for HIV antiviral drugs and includes an emergency clause stating it is necessary for the immediate preservation of public peace, health, or safety. However, the governor partially vetoed the emergency clause section, while approving the remainder of the bill. The bill’s practical effect is to standardize and broaden access to HIV treatment medications within Medicaid by removing utilization-management barriers that can delay or restrict access.

Impact

The bill amends Washington Medicaid law by adding a new section to the chapter governing the Health Care Authority’s administration of Medicaid. It requires coverage of all FDA-approved HIV antiviral drugs without prior authorization or step therapy, affecting both fee-for-service and managed care delivery systems. This changes how Medicaid benefits are administered for enrolled clients and how managed care contracts must be written and renewed, while leaving the underlying drug formulary coverage obligation in place across the program.

Sentiment

The bill appears to have enjoyed broad bipartisan support and little visible opposition. It passed the Senate committee 11-0, the Senate floor 48-0, the House committee 19-0, and the House floor 94-0. The governor approved the bill’s substantive provisions, indicating general agreement with the policy, though the emergency clause was vetoed on the grounds that existing Health Care Authority base expenditures already covered the medications and there was no gap in coverage requiring emergency treatment.

Contention

The main point of contention was not the coverage mandate itself, but the emergency clause. The governor objected to declaring an emergency because, in the veto message, the medications were already covered through existing Health Care Authority base expenditures and there would be no gap in coverage. No other significant policy dispute is reflected in the voting history, which was unanimous in both chambers and committees.

Companion Bills

No companion bills found.

Previously Filed As

WA SB6183

AN ACT Relating to coverage for HIV antiviral drugs;

WA LB252

Prohibit disadvantaging insurance and Medicaid coverage for nonopioid drugs

WA HB1583

AN ACT Relating to medicaid coverage for traditional health care practices;

WA HB2555

Concerning medicaid coverage for traditional health care practices.

WA HB1425

Requiring coverage of pharmacogenomic testing for psychotropic medications.

WA SB6202

Providing coverage for standard fertility preservation services for medicaid enrollees.

WA LB253

Provide for insurance and medicaid coverage of biomarker testing

WA LB68

Provide insurance and medicaid coverage for certain contraceptives

WA LB715

Require insurance coverage for pre-exposure prophylaxis medication

WA HB1093

Providing coverage for massage therapy under medical assistance plans.

Similar Bills

No similar bills found.